Rescue of deficient amygdala tonic γ‐aminobutyric acidergic currents in theFmr–/ymouse model of fragile X syndrome by a novel γ‐aminobutyric acid type A receptor‐positive allosteric modulator

Authors:

Abstract
Alterations in the ratio of excitatory to inhibitory transmission are emerging as a common component of many nervous system disorders, including autism spectrum disorders (ASDs). Tonic γ‐aminobutyric acidergic (GABAergic) transmission provided by peri‐ and extrasynaptic GABA type A (GABAA) receptors powerfully controls neuronal excitability and plasticity and, therefore, provides a rational therapeutic target for normalizing hyperexcitable networks across a variety of disorders, including ASDs. Our previous studies revealed tonic GABAergic deficits in principal excitatory neurons in the basolateral amygdala (BLA) in theFmr1–/yknockout (KO) mouse model fragile X syndrome. To correct amygdala deficits in tonic GABAergic neurotransmission inFmr1–/yKO mice, we developed a novel positive allosteric modulator of GABAAreceptors, SGE‐872, based on endogenously active neurosteroids. This study shows that SGE‐872 is nearly as potent and twice as efficacious for positively modulating GABAAreceptors as its parent molecule, allopregnanolone. Furthermore, at submicromolar concentrations (≤1 μM), SGE‐872 is selective for tonic, extrasynaptic α4β3δ‐containing GABAAreceptors over typical synaptic α1β2γ2 receptors. We further find that SGE‐872 strikingly rescues the tonic GABAergic transmission deficit in principal excitatory neurons in theFmr1–/yKO BLA, a structure heavily implicated in the neuropathology of ASDs. Therefore, the potent and selective action of SGE‐872 on tonic GABAAreceptors containing α4 subunits may represent a novel and highly useful therapeutic avenue for ASDs and related disorders involving hyperexcitability of neuronal networks.
Funding Information
  • Sage Therapeutics, Inc.

This publication has 69 references indexed in Scilit: